Point State Capital LP Bristol Myers Squibb CO Transaction History

Point State Capital LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$72.62 - $79.98 $3.43 Million - $3.78 Million	47,235 Added 100.0%	94,470 $7.27 Million
Q2 2022 Aug 12, 2022	BUY	$72.62 - $79.98 $3.43 Million - $3.78 Million	47,235 New	47,235 $3.64 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $4.76 Million - $5.71 Million	-77,500 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $4.16 Million - $4.85 Million	77,500 New	77,500 $4.83 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $4.56 Million - $5.13 Million	-76,828 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $4.44 Million - $5.03 Million	76,828 New	76,828 $4.77 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $100 Million - $111 Million	-2,244,489 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $101 Million - $121 Million	2,244,489 New	2,244,489 $107 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $1.2 Million - $1.31 Million	-20,000 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $118 Million - $136 Million	-2,139,250 Reduced 99.07%	20,000 $1.28 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,159,250	2,159,250 $120 Million

2,402

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.